生命科学资讯

European Commission approves Roche’s Lunsumio subcutaneous for relapsed or refractory follicular lymphoma - Yahoo Finance

Roche Had A Positive Cancer Study — And Its Rival Flew 130% - Investor's Business Daily

Roche pill notches win in early breast cancer - BioPharma Dive

Roche's oral SERD notches second pivotal breast cancer win - FirstWord Pharma

OLMA Stock Doubles After Roche Cancer Drug Trial Yields Positive Results - Stocktwits

Roche's oral SERD goes 2 for 2, hitting goal in phase 3 adjuvant breast cancer trial - Fierce Biotech

Freenome Announces Exclusive Agreement with Roche to Expand Technology Collaboration and Develop and Commercialize Cancer Screening Tests Outside the U.S. - PR Newswire

Roche touts early giredestrant success | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Roche boosts Olema as breast cancer therapy succeeds in late-stage trial - Seeking Alpha

New experimental drug could transform care for cancer patients - The Independent

Roche Shares Rise After Breast-Cancer Pill Shows Positive Results in Trial - The Wall Street Journal

Is Now the Moment to Reassess Roche After Its Drug Pipeline Developments and 17% Stock Jump? - simplywall.st

Roche reports positive Phase III data of giredestrant for breast cancer - Clinical Trials Arena

Roche oral drug shown to keep breast cancer at bay, boosting shares - Reuters

Roche Gives Glimpse of Cancer Genomics Potential of New Axelios Sequencer - GenomeWeb

Obituary information for Kathleen M. Roche - Cartmell Davis Funeral Home

Ice Bears swap Finstrom for blue liner Roche - Knoxville Ice Bears

Roche’s fenebrutinib shows best-in-disease potential in MS - European Pharmaceutical Review

Roche sizes up first BTK inhibitor approval on Phase III MS victory - Clinical Trials Arena

Artificial Intelligence at Roche Diagnostics - Emerj Artificial Intelligence Research